

NAVIGATING UNCHARTED TERRITORY: CLINICAL PERSPECTIVES ON THE FIELD OF PSYCHEDELICS AND MENTAL HEALTH



REBECCA ROTHBERG, PSYD

NOVEMBER 2, 2024
9:00 AM - 12:30 PM PACIFIC

THE WRIGHT INSTITUTE
2728 DURANT AVE.
BERKELEY, CA 94704
MORNING REFRESHMENTS WILL BE
PROVIDED.



Wright Institute Community: FREE

Wright Institute Faculty, Students, and Staff
Practicum & Internship Supervisors & Training Staff

General Public: \$88

Non-WI Students: \$35

Alums: \$53

Alumni who have completed/updated their Alumni Survey may attend this WI continuing education program for free. Email contact Cassandra Dilosa at cdilosa@wi.edu for more information.

REGISTER BY OCTOBER 30TH

Click or Scan
QR Code



CE Credits: 3.5 CE Hours

The Wright Institute is approved by the American Psychological Association to sponsor continuing education for psychologists. The Wright Institute maintains responsibility for this program and its content.

California LMFTs, LCSWs, LEPs, & LPCCs: The State of California Board of Behavioral Sciences (BBS) no longer approves continuing education providers. Instead, they accept courses from providers approved by various agencies. The Wright Institute is APA-approved, and all our courses are accepted for CE credit by the BBS.

DESCRIPTION

The field of mental health is rapidly evolving, perhaps nowhere as fervently as in the niche of psychedelics. The recent boom in psychedelic science and subsequent introduction of transformational medicines as viable and evidence-based treatments for some of the most intractable psychiatric disorders warrants the attention of clinicians and laypeople alike. This continuing education (CE) course is intended to provide an overview of the current, and rapidly evolving, landscape of psychedelics within the broader field of mental health. Through participation in this course, clinicians of all experience levels will gain a high-level understanding of where current research and policy is regarding the clinical use of psychedelic substances for various psychiatric disorders, gaps in the literature, applications of research into clinical practice, as well as where the field may be headed in the future.

LEARNING OBJECTIVES

- Explain what aspects of PTSD are targeted in MDMA-assisted psychotherapy.
- Compare ketamine and psilocybin-assisted treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).
- Describe the difference between psychedelic and psycholytic dosing in ketamine treatment.
- Identify 1 variable shown to mediate outcomes in psychedelic research.

LEARNING LEVEL: ALL LEVELS

This workshop is suitable for psychologists new to the field, with limited experience, and with extensive experience in the field.

PRESENTER BIO

Dr. Rebecca Rothberg is a Berkeley-based psychotherapist, with a background in the arts, trauma-informed yoga, and working with non-ordinary states of consciousness in both research and clinical settings. She has served on clinical trials involving psychedelics at the Columbia University Medical Center, and published research investigating the role of mystical experience in ketamine treatment for substance use disorders. Dr. Rebecca has co-founded the Graduate Student Association for Psychedelic Studies (GSAPS), and trained with the Multidisciplinary Association for Psychedelic Studies (MAPS), Polaris Insight Center in San Francisco, VA Palo Alto Healthcare System, and Stanford Addiction Medicine Dual Diagnosis Clinic. She currently provides ketamine-assisted psychotherapy (KAP) in her private practice.

Please contact us in advance if you require special accommodations on the day of the workshop.

THE WRIGHT INSTITUTE CONTINUING EDUCATION PROGRAM DOES NOT RECEIVE ANY COMMERCIAL SUPPORT FOR ANY OF OUR PROGRAMS.



[Website](http://www.wi.edu/continuing-education)
www.wi.edu/continuing-education



ce@wi.edu



Contact
510-841-9230